Kidney stones in patients with type 2 diabetes mellitus. Metabolic risk factors

Main Article Content

Francisco Rodolfo Spivacow Elisa Elena del Valle Paula Rey Pablo Martínez Allo Martín Pailler

Abstract

Background: In the past few decades, the prevalence of kidney stones in Western countries has increased in parallel with the growing overweight/obesity and type 2 diabetes mellitus rates. An increased insulin resistance in these patients explains, in part, the rising prevalence of uric acid stones.


Aim: The Aim of this retrospective study was to evaluate the metabolic abnormalities in type 2 diabetic and non-diabetic patients with kidney stones.


Methods: A total of 104 diabetic patients (age: 57.8 ± 11 years) and 130 non-diabetics (age: 52.1 ± 6.7 years) with kidney stones were selected.


Results: Higher rates of body mass index, hypertension, urinary tract infection, gout and hyperuricemia were observed in diabetic patients as compared to the non-diabetics, while similar rates were found for their family history of kidney stones. Metabolic abnormalities were detected in 95.2% and 81.5% of diabetics and non-diabetics, respectively. Idiopathic hypercalciuria was the most frequent abnormality in both groups, although as a simple abnormality, in diabetic patients, unduly acidic urine was the more common.


Conclusions: unduly acidic urine is the most frequent single abnormalities in patients with diabetes mellitus and is in part responsible for the greater number of uric acid stones.

Keywords: Metabolic risk factors, kidney stone, type 2 diabetes

Article Details

How to Cite
SPIVACOW, Francisco Rodolfo et al. Kidney stones in patients with type 2 diabetes mellitus. Metabolic risk factors. Medical Research Archives, [S.l.], v. 11, n. 10, oct. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/4483>. Date accessed: 16 may 2024. doi: https://doi.org/10.18103/mra.v11i10.4483.
Section
Research Articles

References

1. Trinchieri A, Coppi F, Montanari E, Del Nero A, Zanetti G, Pisani E. Increase in the prevalence of symptomatic upper urinary track stones during the last 10 years. Eur Urol 2000; 37:23–25.

2. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010; 12: e86– e96.

3. Morales-Martínez A, Melgarejo-Segura MT, Arraba-Polo Ma. Manejo Médico De la litiasis urinaria. Arch Esp Urol. 2021; 74(1):4-14.

4. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. World J Urol. 2017; Sep;35(9):1301-1320.

5. Hill AH, Basourakos SP, Lewicki P, et al. Incidence of Kidney Stones in The United States: The Continuos National Health and Nutrition Examination Survey J Urol. 2022; 207(4):851-856.

6. Meydan N, Barutca S, Caliskan S, Camsari T. Urinary stone disease in diabetes mellitus. Scaned J Urol Nephrol. 2003; 37:64–70.

7. Taylor EN, Stampfer MJ, Curhan GC. Obesity, Weight Gain, and the Risk of Kidney Stones, JAMA. 2005; 293:455-462.

8. Worceser EM, Coe FL. Calcium Kidney Stones. N Engl J Med. 2010;263: 954-963.

9. Curhan GC, Willet WC, Rimm EB, et al. Family history and Risk of Kidney stones. J AM Soc Nephrol. 1997;8: 1568-1573.

10. Badr AAY, Hazhir S, Hasanzadeh K. Family history and age at the onset of upper urinary tract calculi. Urol J. 2007; 4(3):142-145.

11. Raheem OA, Khandwala YS, Sur RL, et al. Burden of urolithiasis: trends in prevalence, treatments and costs. Eur Urol Focus. 2017; 3:18-26.

12. Adam Halinski, Kamran Hassan Bhatti, Luca Boeri. Stone composition of renal stone formers from different global regions. Arch Ital Urol Androl. 2021; 93(3):307-12.

13. Yanqiong Liu SL, ZIHyu Zeng, Jian Wang, Li Xie, Taijie Li, et al. Kidney stones and cardiovascular risk: a meta-analysis of cohort studies. Am J Kidney Dis 2014;64(3):402-410.

14. Seolhye Kim, Yoosoo Chang , Eunju Sung , et al. Association between sonographically diagnosed neprolithiasis and subclinical coronary calcification in adults. Am J Kidney Dis. 2017; 71(1):35-41.

15. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and risk of nephrolithiasis. Kidney Int. 2005; 68:1230–1235.

16. Abate N, Chandalia M, Cabo-Chan Av Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: Novel features of the renal manifestation of insulin resistance. Kidney Int. 2004; 65:386–392.

17. Pak CY, Sakhaee K, Moe O, et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003; 61:523–527.

18. Pak CY, Poindexter JR, Peterson RD, Koska J, Sakhaee K. Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urology. 2002;60:789–794.

19. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992; 327:1141–1152.

20. Hamm LL. Renal management of citrate. Kidney Int. 1990; 38:728–735.

21. Sakhaee K, Capolongo C, Maalouf NM, Pasch A, Moe OW, Poindexter J, et al Beverley Adams-Huet. Metabolic syndrome and the risk of calcium stones. Nephrol Dial Transplant. 2012; 27:3201–3209.

22. Nowicki M, Kokot F, Surdacki A. The influence of hyperinsulinemia on calcium-phosphate metabolism in renal failure. Nephrol Dial transplant.1998; 13:2566–2571.

23. Daudon M, Traxer O, Conort P, Lacour Bernard, Jungers Paul. Type 2 diabetes increases the risk of uric acid stones. J Am Soc Nephrol. 2006; 17:2026–2033.

24. Weinberg AE, Patel CJ, Chertow GM, Leppert JT. Diabetic severity and risk of kidney stone disease. Eur Urol. 2014; 65:242-247.

25. Fang-Yeh Chu, Ch IH-Chun Chang, Pin-Hao Huang, et al. The association of uric acid stones with obesity, prediabetes, type 2 diabetes mellitus, and hypertension. Biomed Res Int. 2017;7523960

26. Spivacow FR, Abdala R, del Valle EE, Loachamin F, Silveira F, Rey P. Family history and biochemical diagnosis in 1948 kidney stoen formers. Rev Nefrol Dial Traspl. 2017; 37:198-206.

27. Spivacow FR, del Valle EE, Lores E, Rey Paula. Kidney stones: composition, frequency and relationship with metabolic diagnosis. Medicina. 2016; 76:343-348.

28. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004; 65(4):1422-1425.

29. Trincheri A, Croppi E, Montanari E. Obesity and urolithiasis: evidence for regional influences. Urolithiasis. 2017; 45:271-278.

30. Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH. Biochemical profile of idiopathic renal uric acid nephrolithiasis. Kidney Int. 2001; 60:757–761.

31. Eckel RH, Grundy SM, Zimmet PZ.) The metabolic syndrome. Lancet. 2005; 365:1415–1428.

32. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin dependent diabetes mellitus. J Clin Invest. 1994; 94:1714–1721.

33. Kamel KS, Cheema-Dhadli S, Halperin ML.Studies on the pathophysiology of low urinary pH in patients with uric acid stones. Kidney Int. 2002; 61:988– 994.

34. Pollak V, Mattenheimer H. Kidney glutaminase activity in gout. J Lab Clin Med. 1965; 66:564–570.

35. Gutman A, Yue TF. An abnormality of glutamine metabolism in primary gout. Am J Med. 1963; 35:820–831.